Abstract
Key steps in the biodegradable stent revolution, including the first-in-man results of magnesium1,2 and poly-L-lactide (PLLA) stents,3,4 have been reported in The Lancet. With more than 60 000 Absorb bioresorbable vascular scaffolds implanted in the past 3 years, a randomised comparison of metallic and fully bioabsorbable stents, both eluting the antiproliferative drug everolimus, is now presented by Patrick Serruys and colleagues.5 The ABSORB II trial had a 2:1 single-masked design and a small sample population of 501 patients, with sophisticated coprimary endpoints of nitrate-induced vasomotion and changes in minimum lumen diameter (in-stent late loss) at 3 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
